Compositions and methods for treating alzheimer's disease
US-2024376452-A1 · Nov 14, 2024 · US
Inhibition of oncogenic kras-induced GM-CSF production and function
US9901079B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9901079-B2 |
| Application number | US-201214239503-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 20, 2012 |
| Priority date | Aug 18, 2011 |
| Publication date | Feb 27, 2018 |
| Grant date | Feb 27, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is directed to methods of inhibiting tumor growth in a subject. The present invention is further directed to methods of diagnosing cancer in a subject and identifying a suitable course of treatment for the subject based on the diagnosis. The present invention is also directed to an orthotopic animal model of pancreatic cancer.
First claim
Opening claim text (preview).
What is claimed: 1. A method of enhancing anti-tumor immunity in a subject having pancreatic cancer comprising: selecting a subject having a pancreatic tumor, wherein the pancreatic tumor cells comprise an activated ras oncogene; and administering to the selected subject an agent that inhibits GM-CSF in an amount effective to decrease myeloid derived suppressor cell immunosuppression in the subject, thereby enhancing anti-tumor immunity in the subject. 2. The method of claim 1 , wherein the activated oncogene is KRas. 3. The method of claim 1 , wherein the agent is an antibody or binding fragment thereof that recognizes GM-CSF. 4. The method of claim 3 , wherein the antibody comprises MOR103. 5. The method of claim 1 , wherein said administering is carried out in combination with one or more additional cancer related therapies or therapeutics. 6. The method of claim 1 , wherein the agent that inhibits GM-CSF is administered directly to the tumor site. 7. The method of claim 1 , wherein the agent that inhibits GM-CSF is coupled to a tumor cell targeting ligand to target delivery of the agent to said tumor cells.
Assignees
Inventors
Classifications
Colony Stimulating Factors · CPC title
Antineoplastic agents · CPC title
for cancer (immunoassay for cancer G01N33/575) · CPC title
- A61K31/713Primary
Double-stranded nucleic acids or oligonucleotides · CPC title
against CD8 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9901079B2 cover?
- The present invention is directed to methods of inhibiting tumor growth in a subject. The present invention is further directed to methods of diagnosing cancer in a subject and identifying a suitable course of treatment for the subject based on the diagnosis. The present invention is also directed to an orthotopic animal model of pancreatic cancer.
- Who is the assignee on this patent?
- Bar Sagi Dafna, Pylayeva Gupta Yuliya, Lee Kyoung Eun, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/713. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).